Literature DB >> 2237915

Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals.

M Machida1, H Kusajima, H Aijima, A Maeda, R Ishida, H Uchida.   

Abstract

A toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals was undertaken using nalidixic acid as a standard drug. Norfloxacin and nalidixic acid were subcutaneously administered to rats and rabbits, orally administered to dogs, and norfloxacin was orally dosed to monkeys once a day for 7 consecutive days. Of the dose levels tested, the minimum arthropathic doses of norfloxacin were 100, 25, and 50 mg/kg/day in rats, rabbits, and dogs, respectively. At these doses, the peak serum concentrations (Cmax) on Day 6 were 16.1, 9.73, and 5.11 micrograms/ml, and the areas under the serum concentration/time curve (AUC0----infinity) were 31.9, 22.9, and 26.2 micrograms.hr/ml, in respective animals. Monkeys showed no arthropathy with norfloxacin at doses of less than 500 mg/kg/day, at which the Cmax and AUC0----infinity were 15.6 micrograms/ml and 103 micrograms.hr/ml, respectively. The minimum arthropathic doses of nalidixic acid were 50, 100, and 25 mg/kg/day in rats, rabbits, and dogs, respectively. The Cmax and AUC0----infinity of nalidixic acid were higher than those of norfloxacin in all animals. Joint tissues took up more norfloxacin than nalidixic acid, but when arthropathy was present the articular cartilage concentrations of the two drugs were in the same range. The penetration of norfloxacin into the articular cartilage was the same regardless of the joint's anatomical locations, but differed among species, being highest in rats and lowest in monkeys. The Cmax and AUC0----infinity of norfloxacin in animals at their arthropathic doses were far higher than those measured clinically in children, whereas those of nalidixic acid in animals did not differ much from its clinical parameters.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2237915     DOI: 10.1016/0041-008x(90)90144-j

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  13 in total

1.  A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects.

Authors:  G Hayem; C Carbon
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis.

Authors:  Kevin M Watt; Matthew M Massaro; Brian Smith; Michael Cohen-Wolkowiez; Daniel K Benjamin; Matthew M Laughon
Journal:  Pediatr Infect Dis J       Date:  2012-02       Impact factor: 2.129

3.  Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice.

Authors:  M A Simonin; P Gegout-Pottie; A Minn; P Gillet; P Netter; B Terlain
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 4.  Quinolones in children. Are concerns over arthropathy justified?

Authors:  R Stahlmann; C Förster; D Van Sickle
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

5.  The effects of ciprofloxacin on human chondrocytes in cell culture.

Authors:  M A Mont; S K Mathur; C G Frondoza; D S Hungerford
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

Review 6.  Safety Concerns Surrounding Quinolone Use in Children.

Authors:  Karisma Patel; Jennifer L Goldman
Journal:  J Clin Pharmacol       Date:  2016-03-28       Impact factor: 3.126

Review 7.  Use of the quinolones in paediatrics.

Authors:  U B Schaad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats.

Authors:  R Stahlmann; U Zippel; C Förster; R Schwabe; M Shakibaei; H J Merker; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo.

Authors:  M Kato; S Takada; S Ogawara; S Takayama
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Antibiotic Treatment of Dogs and Cats during Pregnancy.

Authors:  Marcela Rebuelto; María Elena Loza
Journal:  Vet Med Int       Date:  2010-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.